Li D, Fish PV, Mano T (2012) Bridging solubility between drug discovery and development. Drug Discov Today 17:486–495. https://doi.org/10.1016/j.drudis.2011.11.007

Article  CAS  Google Scholar 

Jones HM, Gardner IB, Watson KJ (2009) Modelling and PBPK simulation in drug discovery. The AAPS J 11:155–166. https://doi.org/10.1208/s12248-009-9088-1

Article  CAS  PubMed  Google Scholar 

Honorio KM, Moda TL, Andricopulo AD (2013) Pharmacokinetic properties and in silico ADME modeling in drug discovery. Med Chem 9:163–176. https://doi.org/10.2174/1573406411309020002

Article  CAS  PubMed  Google Scholar 

Dodd S, Kollipara S, Sanchez-Felix M, Kim H et al (2019) Prediction of ARA/PPI drug-drug interactions at the drug discovery and development interface. J Pharm Sci 108:87–101. https://doi.org/10.1016/j.xphs.2018.10.032

Article  CAS  PubMed  Google Scholar 

Rajman I (2008) PK/PD modelling and simulations: utility in drug development. Drug Discov Today 13:341–346. https://doi.org/10.1016/j.drudis.2008.01.003

Article  CAS  PubMed  Google Scholar 

Boddu R, Kollipara S, Vijaywargi G, Ahmed T (2023) Power of integrating PBPK with PBBM (PBPK-BM): a single model predicting food effect, gender impact, drug-drug interactions and bioequivalence in fasting & fed conditions. Xenobiotica 53:260–278. https://doi.org/10.1080/00498254.2023.2238048

Article  CAS  PubMed  Google Scholar 

Poulin P, Theil FP (2002) Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition. J Pharm Sci 91:1358–1370. https://doi.org/10.1002/jps.10128

Article  CAS  PubMed  Google Scholar 

Wu D, Sanghavi M, Kollipara S, Ahmed T et al (2023) Physiologically based pharmacokinetics modeling in biopharmaceutics: case studies for establishing the bioequivalence safe space for innovator and generic drugs. Pharm Res 40:337–357. https://doi.org/10.1007/s11095-022-03319-6

Article  CAS  PubMed  Google Scholar 

Bhattiprolu AK, Kollipara S, Ahmed T, Boddu R, Chachad S (2022) Utility of Physiologically Based Biopharmaceutics Modeling (PBBM) in regulatory perspective: application to supersede f2, enabling biowaivers & creation of dissolution safe space. J Pharm Sci 111:3397–3410. https://doi.org/10.1016/j.xphs.2022.09.003

Article  CAS  PubMed  Google Scholar 

Jaiswal S, Ahmed T, Kollipara S, Bhargava M, Chachad S (2021) Development, validation and application of physiologically based biopharmaceutics model to justify the change in dissolution specifications for DRL ABC extended release tablets. Drug Dev Ind Pharm 47:778–789. https://doi.org/10.1080/03639045.2021.1934870

Article  CAS  PubMed  Google Scholar 

Ahmed T, Kollipara S, Boddu R, Bhattiprolu AK (2023) Biopharmaceutics risk assessment—connecting critical bioavailability attributes with in vitro, in vivo properties and physiologically based biopharmaceutics modeling to enable generic regulatory submissions. AAPS J 25:77. https://doi.org/10.1208/s12248-023-00837-y

Article  PubMed  Google Scholar 

Kollipara S, Boddu R, Ahmed T, Chachad S (2022) Simplified model-dependent and model-independent approaches for dissolution profile comparison for oral products: regulatory perspective for generic product development. AAPS PharmSciTech 23:53. https://doi.org/10.1208/s12249-021-02203-7

Article  PubMed  Google Scholar 

Wu F, Shah H, Li M, Duan P et al (2021) Biopharmaceutics applications of physiologically based pharmacokinetic absorption modeling and simulation in regulatory submissions to the US food and drug administration for new drugs. The AAPS J 23:1–4. https://doi.org/10.1208/s12248-021-00564-2

Article  Google Scholar 

Heimbach T, Kesisoglou F, Novakovic J et al (2021) Establishing the bioequivalence safe space for immediate-release oral dosage forms using Physiologically Based Biopharmaceutics Modeling (PBBM): case studies. J Pharm Sci 110:3896–3906. https://doi.org/10.1016/j.xphs.2021.09.017

Article  CAS  PubMed  Google Scholar 

Cristofoletti R, Patel N, Dressman JB (2017) Assessment of bioequivalence of weak base formulations under various dosing conditions using physiologically based pharmacokinetic simulations in virtual populations. Case examples: ketoconazole and posaconazole. J Pharm Sci 106:560–569. https://doi.org/10.1016/j.xphs.2016.10.008

Article  CAS  PubMed  Google Scholar 

Huang SM, Abernethy DR, Wang Y, Zhao P, Zineh I (2013) The utility of modeling and simulation in drug development and regulatory review. J Pharm Sci 102:2912–2923. https://doi.org/10.1002/jps.23570

Article  CAS  PubMed  Google Scholar 

Mistry B, Patel N, Jamei M, Rostami-Hodjegan A, Martinez MN (2016) Examining the use of a mechanistic model to generate an in vivo/in vitro correlation: journey through a thought process. The AAPS J 18:1144–1158. https://doi.org/10.1208/s12248-016-9930-1

Article  PubMed  Google Scholar 

Davies B, Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093–1095. https://doi.org/10.1023/A:1018943613122

Article  CAS  PubMed  Google Scholar 

Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Del Rev 23:3–25. https://doi.org/10.1016/S0169-409X(96)00423-1

Article  CAS  Google Scholar 

Testa B, Crivori P, Reist M, Carrupt PA (2000) The influence of lipophilicity on the pharmacokinetic behavior of drugs: concepts and examples. Perspect Drug Discov Des 19:179–211. https://doi.org/10.1023/A:1008741731244

Article  CAS  Google Scholar 

Waring MJ (2010) Lipophilicity in drug discovery. Expert Opin Drug Discov 5:235–248. https://doi.org/10.1517/17460441003605098

Article  CAS  PubMed  Google Scholar 

Khalil F, Läer S (2011) Physiologically based pharmacokinetic modeling: methodology, applications, and limitations with a focus on its role in pediatric drug development. J Biomed Biotechnol 1:907461. https://doi.org/10.1155/2011/907461

Article  CAS  Google Scholar 

Yuvaneshwari K, Kollipara S, Ahmed T, Chachad S (2022) Applications of PBPK/PBBM modeling in generic product development: an industry perspective. J Drug Del Sci Technol 69:103152. https://doi.org/10.1016/j.jddst.2022.103152

Article  CAS  Google Scholar 

Laisney M, Heimbach T et al (2022) Physiologically based biopharmaceutics modeling to demonstrate virtual bioequivalence and bioequivalence safe-space for ribociclib which has permeation rate-controlled absorption. J Pharm Sci 111:274–284. https://doi.org/10.1016/j.xphs.2021.10.017

Article  CAS  PubMed  Google Scholar 

Jereb R, Kristl A, Mitra A (2020) Prediction of fasted and fed bioequivalence for immediate release formulations using physiologically based biopharmaceutics modeling (PBBM). Eur J Pharm Sci 155:105554. https://doi.org/10.1016/j.ejps.2020.105554

Article  CAS  PubMed  Google Scholar 

Wedagedera J, Cain T, Pathak SM, Jamei M Virtual bioequivalence assessment of two tramadol formulations using the advanced dissolution absorption and metabolism (ADAM) model via Simcyp R Package. https://www.certara.com/poster/virtual-bioequivalence-assessment-of-two-tramadol-formulations-using-the-advanced-dissolution-absorption-and-metabolism-adam-model-via-simcyp-r-package/ Accessed 21st May 2024

Doki K, Darwich AS, Patel N, Rostami-Hodjegan A (2017) Virtual bioequivalence for achlorhydric subjects: the use of PBPK modelling to assess the formulation-dependent effect of achlorhydria. Eur J Pharm Sci 109:111–120. https://doi.org/10.1016/j.ejps.2017.07.035

Article  CAS  PubMed  Google Scholar 

Loisios-Konstantinidis I, Hens B, Mitra A et al (2020) Using physiologically based pharmacokinetic modeling to assess the risks of failing bioequivalence criteria: a tale of two ibuprofen products. The AAPS J 22:1–9. https://doi.org/10.1208/s12248-020-00495-4

Article  CAS  Google Scholar 

Hartmanshenn C, Scherholz M, Androulakis IP (2016) Physiologically-based pharmacokinetic models: approaches for enabling personalized medicine. J Pharmacokinet Pharmacodyn 43:481–504. https://doi.org/10.1007/s10928-016-9492-y

Article  CAS  PubMed  PubMed Central